Consumer Insights
Uncover trends and behaviors shaping consumer choices today
Procurement Insights
Optimize your sourcing strategy with key market data
Industry Stats
Stay ahead with the latest trends and market analysis.
Vaso occlusive crisis is the most common clinical manifestation of sickle cell disease. It is responsible for a significant volume of hospitalizations and emergency department visits by the affected patients. Recent studies suggest that nearly half of the people suffering from sickle cell disease experience vaso occlusive crisis, with some patients having 6 or more such episodes every year. Repeated episodes can lead to severe health complications and thus, there is a heightened impetus to develop effective drugs to alleviate the condition.
The Vaso Occlusive Crisis Drug Pipeline Insight Report by Expert Market Research gives comprehensive insights into vaso occlusive crisis drugs currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for vaso occlusive crisis. The report includes the analysis of over 100 pipeline drugs and 50+ companies. The vaso occlusive crisis pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials including their adverse effects on patients suffering from vaso occlusive crisis.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to vaso occlusive crisis.
A vaso occlusive crisis, or VOC, refers to a condition when sickled red blood cells block the flow of blood to the extent that the tissues experience oxygen deprivation. This triggers an inflammatory response that leads to substantial pain which primarily occurs in the chest, back, or extremities. Besides causing acute pain, a vaso occlusive event can make the patient prone to various health issues such as strokes, arthritis, and kidney failure.
For the acute management of vaso occlusive crisis, opioids are commonly given to the patient for pain relief. Hydroxyurea, an antimetabolite chemotherapeutic agent, is also widely used to prevent painful crises in sickle cell anemia patients. In recent years, Adakveo (crizanlizumab) and Endari (L-glutamine) were cleared by the US Food and Drug Administration (FDA) as vaso occlusive crisis-preventing therapies. Furthermore, in December 2023, a major milestone was achieved with the FDA approval of the first-ever cell-based gene therapy based on CRISPR/Cas9, Casgevy, for the treatment of sickle cell disease patients aged 12 years and above with recurrent vaso-occlusive crises. The rise in the development and regulatory approval of novel gene therapies are among the major trends, impacting the drug pipeline outlook positively.
This section of the report covers the analysis of vaso occlusive crisis drugs based on several segmentations including:
By Phase
By Drug Class
By Route of Administration
The report covers phase I, phase II, phase III, phase IV, and early phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase II covers a major share of the total clinical trials for vaso occlusive crisis. There are around 31 drugs in phase II for vaso occlusive crisis.
The drug molecules categories covered under vaso occlusive crisis pipeline analysis include analgesics, anti-sickling agents, monoclonal antibodies, amino acid supplements, and gene therapy. These drugs are prescribed according to the symptoms and the underlying cause of vaso occlusive crisis.
The EMR report for the vaso occlusive crisis drug pipeline covers the profile of key companies involved in clinical trials and their drugs under development. Below is the list of a few players involved in vaso occlusive crisis clinical trials:
Major drugs currently in the drug pipeline are as follows:
Sponsored by Hoffmann-La Roche, the drug is being investigated as an adjunct treatment to help prevent vaso-occlusive episodes (VOE) in sickle cell disease. The study is being conducted at 41 locations including the United States and Brazil.
The Phase 3 study, involving inclacumab (a P-selectin inhibitor), is sponsored by Pfizer. The safety and effic...
Sufentanil is an opioid analgesic, currently in Phase III clinical development. The INVOPE trial will evaluate...
Crizanlizumab is a monoclonal antibody medication, used to reduce the frequency of vaso-occlusive crises. Nova...
The Vaso Occlusive Crisis Drug Pipeline Insight Report provides a strategic overview of the latest and future landscape of treatments for vaso occlusive crisis. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into market trends, regulatory environments, and potential growth opportunities within vaso occlusive crisis pipeline insights.
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
Scope of the Report |
Details |
Drug Pipeline by Clinical Trial Phase? |
|
Route of Administration? |
|
Drug Classes? |
|
Leading Sponsors Covered? |
|
Geographies Covered? |
|
Purchase Full Report
Datasheet
USD 1,999
tax inclusive*
Single User License
One User
USD 2,499
tax inclusive*
Five User License
Five Users
USD 3,499
tax inclusive*
Corporate License
Unlimited Users
USD 4,499
tax inclusive*
How To Order
Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Australia
63 Fiona Drive, Tamworth, NSW
+61 448 06 17 27
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-858-608-1494
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.
+63 287899028, +63 967 048 3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84865399124